FELIX GALLEGOS, CAMILO EDGAR VINICIO

Preferred name

Main Affiliation

Facultad de Ciencias de la Salud Eugenio Espejo

CENIEC - Grupo de Investigación de Enfermedades Crónicas

Web Site

Google Scholar

ORCID

0000-0003-0224-2321

Scopus Author ID

57210396829

Now showing 1 - 10 of 23

Some of the metrics are blocked by your
consent settings
Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries - PURE: a prospective cohort study
(Elsevier BV, 2020-07)
Marjan Walli-Attaei
;
Philip Joseph
;
Annika Rosengren
;
Clara K Chow
;
Sumathy Rangarajan
Scopus© Citations 313
Some of the metrics are blocked by your
consent settings
Heart Failure Among 173,000 Community-Dwelling Participants From 25 Low-, Middle-, and High-Income Countries in the PURE Study
(Elsevier BV, 2026-06)
Johansson Bartolini, Isabelle
;
Joseph, Philip
;
Islam, Shofiqul
;
Ramachan, Shameena P.
;
Rosengren, Annika
Scopus© Citations 4
Some of the metrics are blocked by your
consent settings
Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial
(Elsevier BV, 2017-08)
Jackie Bosch
;
John W. Eikelboom
;
Stuart J. Connolly
;
Nancy Cook Bruns
;
Vivian Lanius
Scopus© Citations 169
Some of the metrics are blocked by your
consent settings
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
(Elsevier BV, 2022-12)
John W Eikelboom
;
Sanjit S Jolly
;
Emilie P Belley-Cote
;
Richard P Whitlock
;
Sumathy Rangarajan
Scopus© Citations 25
Some of the metrics are blocked by your
consent settings
Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial
(Elsevier BV, 2021-08)
David Collister
;
Lawrence Mbuagbaw
;
Gordon Guyatt
;
P.J. Devereaux
;
Karthik K. Tennankore
Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
(Elsevier BV, 2018-01)
Stuart J Connolly
;
John W Eikelboom
;
Jackie Bosch
;
Gilles Dagenais
;
Leanne Dyal
Scopus© Citations 388
Some of the metrics are blocked by your
consent settings
Obesity and Preeclampsia: Common Pathophysiological Mechanisms
(Frontiers Media SA, 2018-12-19)
LOPEZ JARAMILLO, JOSÉ PATRICIO
;
Juan Barajas
;
Sandra M. Rueda-Quijano
;
Cristina Lopez-Lopez
;
FELIX GALLEGOS, CAMILO EDGAR VINICIO
Scopus© Citations 166
Some of the metrics are blocked by your
consent settings
Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study
(Elsevier BV, 2024-08)
Raed A Joundi
;
Bo Hu
;
Sumathy Rangarajan
;
Darryl P Leong
;
Shofiqul Islam
Background: The focus of most epidemiological studies has been mortality or clinical events, with less information on activity limitations related to basic daily functions and their consequences. Standardised data from multiple countries at different economic levels in different regions of the world on activity limitations and their associations with clinical outcomes are sparse. We aimed to quantify the prevalence of activity limitations and use of assistive devices and the association of limitations with adverse outcomes in 25 countries grouped by different economic levels. Methods: In this analysis, we obtained data from individuals in 25 high-income, middle-income, and low-income countries from the Prospective Urban Rural Epidemiological (PURE) study (175 660 participants). In the PURE study, individuals aged 35–70 years who intended to continue living in their current home for a further 4 years were invited to complete a questionnaire on activity limitations. Participant follow-up was planned once every 3 years either by telephone or in person. The activity limitation screen consisted of questions on self-reported difficulty with walking, grasping, bending, seeing close, seeing far, speaking, hearing, and use of assistive devices (gait, vision, and hearing aids). We estimated crude prevalence of self-reported activity limitations and use of assistive devices, and prevalence standardised by age and sex. We used logistic regression to additionally adjust prevalence for education and socioeconomic factors and to estimate the probability of activity limitations and assistive devices by age, sex, and country income. We used Cox frailty models to evaluate the association between each activity limitation with mortality and clinical events (cardiovascular disease, heart failure, pneumonia, falls, and cancer). The PURE study is registered with ClinicalTrials.gov, NCT03225586. Findings: Between Jan 12, 2001, and May 6, 2019, 175 584 individuals completed at least one question on the activity limitation questionnaire (mean age 50·6 years [SD 9·8]; 103 625 [59%] women). Of the individuals who completed all questions, mean follow-up was 10·7 years (SD 4·4). The most common self-reported activity limitations were difficulty with bending (23 921 [13·6%] of 175 515 participants), seeing close (22 532 [13·4%] of 167 801 participants), and walking (22 805 [13·0%] of 175 554 participants); prevalence of limitations was higher with older age and among women. The prevalence of all limitations standardised by age and sex, with the exception of hearing, was highest in low-income countries and middle-income countries, and this remained consistent after adjustment for socioeconomic factors. The use of gait, visual, and hearing aids was lowest in low-income countries and middle-income countries, particularly among women. The prevalence of seeing close limitation was four times higher (6257 [16·5%] of 37 926 participants vs 717 [4·0%] of 18 039 participants) and the prevalence of seeing far limitation was five times higher (4003 [10·6%] of 37 923 participants vs 391 [2·2%] of 18 038 participants) in low-income countries than in high-income countries, but the prevalence of glasses use in low-income countries was half that in high-income countries. Walking limitation was most strongly associated with mortality (adjusted hazard ratio 1·32 [95% CI 1·25–1·39]) and most consistently associated with other clinical events, with other notable associations observed between seeing far limitation and mortality, grasping limitation and cardiovascular disease, bending limitation and falls, and between speaking limitation and stroke. Interpretation: The global prevalence of activity limitations is substantially higher in women than men and in low-income countries and middle-income countries compared with high-income countries, coupled with a much lower use of gait, visual, and hearing aids. Strategies are needed to prevent and mitigate activity limitations globally, with particular emphasis on low-income countries and women. Funding: Funding sources are listed at the end of the Article.
Scopus© Citations 17
Some of the metrics are blocked by your
consent settings
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis
(Ovid Technologies (Wolters Kluwer Health), 2019-10-29)
John W. Eikelboom
;
Stuart J. Connolly
;
Jacqueline Bosch
;
Olga Shestakovska
;
Victor Aboyans
<jats:sec> <jats:title>Background:</jats:title> <jats:p>Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the first manifestation of underlying cancer.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) and determined the hazard of new cancer diagnosis after bleeding at these sites.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Of 27 395 patients enrolled (mean age, 68 years; women, 21%), 2678 (9.8%) experienced any (major or minor) bleeding, 713 (2.6%) experienced major bleeding, and 1084 (4.0%) were diagnosed with cancer during a mean follow-up of 23 months. Among 2678 who experienced bleeding, 257 (9.9%) were subsequently diagnosed with cancer. Gastrointestinal bleeding was associated with a 20-fold higher hazard of new gastrointestinal cancer diagnosis (7.4% versus 0.5%; hazard ratio [HR], 20.6 [95% CI, 15.2–27.8]) and 1.7-fold higher hazard of new nongastrointestinal cancer diagnosis (3.8% versus 3.1%; HR, 1.70 [95% CI, 1.20–2.40]). Genitourinary bleeding was associated with a 32-fold higher hazard of new genitourinary cancer diagnosis (15.8% versus 0.8%; HR, 32.5 [95% CI, 24.7–42.9]), and urinary bleeding was associated with a 98-fold higher hazard of new urinary cancer diagnosis (14.2% versus 0.2%; HR, 98.5; 95% CI, 68.0–142.7). Nongastrointestinal, nongenitourinary bleeding was associated with a 3-fold higher hazard of nongastrointestinal, nongenitourinary cancers (4.4% versus 1.9%; HR, 3.02 [95% CI, 2.32–3.91]).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>In patients with atherosclerosis treated with antithrombotic drugs, any gastrointestinal or genitourinary bleeding was associated with higher rates of new cancer diagnosis. Any gastrointestinal or genitourinary bleeding should prompt investigation for cancers at these sites.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trial Registration:</jats:title> <jats:p> URL: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> . Unique identifier: NCT01776424. </jats:p> </jats:sec>
Scopus© Citations 52
Some of the metrics are blocked by your
consent settings
Low levels of awareness, treatment, and control of hypertension in Andean communities of Ecuador
(Wiley, 2020-08-15)
FELIX GALLEGOS, CAMILO EDGAR VINICIO
;
Manuel E. Baldeon
;
Federico Zertuche
;
Marco Fornasini
;
Maria Jose Paucar
<jats:title>Abstract</jats:title><jats:p>The major burden of hypertension (HTN) occurs in low‐middle‐income countries (LMIC) and it is the main modifiable risk factor for cardiovascular diseases (CVD). Few population studies on HTN prevalence have been carried out in Ecuador where there is limited information regarding its prevalence, awareness, treatment, and control. Thus, the aim of the present study was to determine the prevalence, awareness, treatment, and control of HTN and its association with socio‐economic, nutritional, and lifestyle habits in urban and rural Andean communities of Pichincha province in Ecuador. The authors studied 2020 individuals aged 35‐70 years (mean age 50.8 years, 72% women), included in the Ecuadorian cohort of the Prospective Urban and Rural Epidemiology (PURE) study, from February to December 2018. The hypertension prevalence (>140/90 mmHg) was 27% and was greater in urban than in rural communities, more common in men, in individuals older than 50 years of age, in people with low monthly income and low level of education. Higher prevalence was also observed in subjects with obesity, and among former smokers and those who consumed alcohol. Only 49% of those with HTN were aware of their condition, 40% were using antihypertensive medications, and 19% had their blood pressure under control (<140/90 mmHg). These results showed low levels of awareness, treatment, and control of HTN in the Andean region of Ecuador, suggesting the urgent necessity of implementing programs to improve the diagnosis and management of HTN.</jats:p>
Scopus© Citations 10

FELIX GALLEGOS, CAMILO EDGAR VINICIO

Filters

Settings

Sort By

Results per page